Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Viking Therapeutics, Inc.
Viking Therapeutics, Inc. News
Viking Therapeutics, Inc. Quantitative Score
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Viking Therapeutics, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Viking Therapeutics, Inc. Financials
Table Compare
Compare VKTX metrics with: | |||
|---|---|---|---|
Earnings & Growth | VKTX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | VKTX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | VKTX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | VKTX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Viking Therapeutics, Inc. Income
Viking Therapeutics, Inc. Balance Sheet
Viking Therapeutics, Inc. Cash Flow
Viking Therapeutics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Viking Therapeutics, Inc. Executives
| Name | Role |
|---|---|
| Dr. Brian Lian Ph.D. | President, Chief Executive Officer & Director |
| Ms. Marianne Mancini | Chief Operating Officer |
| Mr. Gregory S. Zante CPA, CPA | Chief Financial Officer |
| Mr. Michael Morneau | Vice President of Finance & Administration |
| Dr. Geoffrey E. Barker Ph.D. | Chief Development Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Brian Lian Ph.D. | President, Chief Executive Officer & Director | 1966 | 1.19M | |
| Ms. Marianne Mancini | Chief Operating Officer | Female | 1965 | 735K |
| Mr. Gregory S. Zante CPA, CPA | Chief Financial Officer | Male | 1971 | 713K |
| Mr. Michael Morneau | Vice President of Finance & Administration | Male | 1965 | 375.33K |
| Dr. Geoffrey E. Barker Ph.D. | Chief Development Officer | -- |
Viking Therapeutics, Inc. Insider Trades
| Date | 11 Apr |
| Name | FOEHR MATTHEW W |
| Role | Director |
| Transaction | Acquired |
| Type | M-Exempt |
| Shares | 20786 |
| Date | 11 Apr |
| Name | FOEHR MATTHEW W |
| Role | Director |
| Transaction | Disposed |
| Type | M-Exempt |
| Shares | 20786 |
| Date | 31 Mar |
| Name | Rouan Sarah Kathryn |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 1240 |
| Date | 3 Jan |
| Name | Lian Brian |
| Role | President & CEO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 92800 |
| Date | 3 Jan |
| Name | Lian Brian |
| Role | President & CEO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 163333 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 11 Apr | FOEHR MATTHEW W | Director | Acquired | M-Exempt | 20786 |
| 11 Apr | FOEHR MATTHEW W | Director | Disposed | M-Exempt | 20786 |
| 31 Mar | Rouan Sarah Kathryn | Director | Acquired | P-Purchase | 1240 |
| 3 Jan | Lian Brian | President & CEO | Acquired | A-Award | 92800 |
| 3 Jan | Lian Brian | President & CEO | Acquired | A-Award | 163333 |